Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott

ABSTRACT

BACKGROUND: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored. METHODS: Reports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were queried from the PROCLAIMSM database. Patient characteristics, toxicity and efficacy were analyzed. RESULTS: A total of 57 patients (40 mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4 complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2 observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2 requiring steroid therapy. CONCLUSION: In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy. More... »

PAGES

49

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3

DOI

http://dx.doi.org/10.1186/s40425-019-0522-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112212877

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30777131


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Dana Farber Cancer Institute, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buchbinder", 
        "givenName": "Elizabeth I.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cancer Research Foundation of NY, Chappaqua,, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dutcher", 
        "givenName": "Janice P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Diego", 
          "id": "https://www.grid.ac/institutes/grid.266100.3", 
          "name": [
            "Moores UCSD Cancer Center, La Jolla, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daniels", 
        "givenName": "Gregory A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Providence Health & Services", 
          "id": "https://www.grid.ac/institutes/grid.415286.c", 
          "name": [
            "Providence Health & Services, Portland, OR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curti", 
        "givenName": "Brendan D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Sapna P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Minnesota", 
          "id": "https://www.grid.ac/institutes/grid.17635.36", 
          "name": [
            "University of Minnesota, Minneapolis, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holtan", 
        "givenName": "Shernan G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology\\Oncology Clinic", 
          "id": "https://www.grid.ac/institutes/grid.490187.3", 
          "name": [
            "Hematology/Oncology Clinic, Baton Rouge, LA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miletello", 
        "givenName": "Gerald P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Moffitt Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.468198.a", 
          "name": [
            "Moffitt Cancer Center, Tampa, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fishman", 
        "givenName": "Mayer N.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Anschutz Medical Campus", 
          "id": "https://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "University of Colorado, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gonzalez", 
        "givenName": "Rene", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Loyola University Chicago", 
          "id": "https://www.grid.ac/institutes/grid.164971.c", 
          "name": [
            "Loyola University Stritch School of Medicine, Maywood, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clark", 
        "givenName": "Joseph I.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Saint Louis University", 
          "id": "https://www.grid.ac/institutes/grid.262962.b", 
          "name": [
            "Saint Louis University, 63110, Saint Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richart", 
        "givenName": "John M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Michigan\u2013Ann Arbor", 
          "id": "https://www.grid.ac/institutes/grid.214458.e", 
          "name": [
            "University of Michigan, Ann Arbor, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lao", 
        "givenName": "Christopher D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fred Hutchinson Cancer Research Center", 
          "id": "https://www.grid.ac/institutes/grid.270240.3", 
          "name": [
            "University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tykodi", 
        "givenName": "Scott S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rutgers University", 
          "id": "https://www.grid.ac/institutes/grid.430387.b", 
          "name": [
            "Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Silk", 
        "givenName": "Ann W.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beth Israel Deaconess Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239395.7", 
          "name": [
            "Beth Israel Deaconess Medical Center, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McDermott", 
        "givenName": "David F.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30126-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002679693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1414428", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007696832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1823", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010268280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)60958-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012632588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0142(19980815)83:4<797::aid-cncr25>3.0.co;2-m", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015678740"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0092-8674(93)90152-g", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016163477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019970557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024843336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci67008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046164943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.53.0105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047895673"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1003466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052212829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1995.13.3.688", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082550218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-018-0387-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105882929", 
          "https://doi.org/10.1186/s40425-018-0387-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored.\nMETHODS: Reports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were queried from the PROCLAIMSM database. Patient characteristics, toxicity and efficacy were analyzed.\nRESULTS: A total of 57 patients (40\u2009mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4 complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2 observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2 requiring steroid therapy.\nCONCLUSION: In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-019-0522-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition", 
    "pagination": "49", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "146eee18ba798c34ddab163ca5fb25a2f73b2b963ebe466713cabcacbddbd2ae"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30777131"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-019-0522-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112212877"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-019-0522-3", 
      "https://app.dimensions.ai/details/publication/pub.1112212877"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113664_00000005.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-019-0522-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      42 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-019-0522-3 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author Nf2d6de3331144867953becb5bc27109d
4 schema:citation sg:pub.10.1186/s40425-018-0387-x
5 https://doi.org/10.1002/(sici)1097-0142(19980815)83:4<797::aid-cncr25>3.0.co;2-m
6 https://doi.org/10.1016/0092-8674(93)90152-g
7 https://doi.org/10.1016/s0140-6736(14)60958-2
8 https://doi.org/10.1016/s1470-2045(16)30126-7
9 https://doi.org/10.1056/nejmoa1003466
10 https://doi.org/10.1056/nejmoa1414428
11 https://doi.org/10.1056/nejmoa1504030
12 https://doi.org/10.1056/nejmoa1510665
13 https://doi.org/10.1158/1078-0432.ccr-11-1823
14 https://doi.org/10.1172/jci67008
15 https://doi.org/10.1200/jco.1995.13.3.688
16 https://doi.org/10.1200/jco.2013.53.0105
17 schema:datePublished 2019-12
18 schema:datePublishedReg 2019-12-01
19 schema:description BACKGROUND: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored. METHODS: Reports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were queried from the PROCLAIMSM database. Patient characteristics, toxicity and efficacy were analyzed. RESULTS: A total of 57 patients (40 mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4 complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2 observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2 requiring steroid therapy. CONCLUSION: In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy.
20 schema:genre research_article
21 schema:inLanguage en
22 schema:isAccessibleForFree true
23 schema:isPartOf Ne311912140b54bdcb339417314276827
24 Nf9e45a9dacd844b189c70076f64b4a5e
25 sg:journal.1049249
26 schema:name Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
27 schema:pagination 49
28 schema:productId N1d43cc30b6da43f08add5b9e4fb5bb7f
29 N38b9cf2d84c64a72b5018ea44c850127
30 N4320f0ac0e9a4f4daaf22afc99f4c34b
31 N9976f5dfd0d84c49b150c8cf2354ae04
32 Ne844f4e984cc49a083298f38f3e4815d
33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112212877
34 https://doi.org/10.1186/s40425-019-0522-3
35 schema:sdDatePublished 2019-04-11T10:35
36 schema:sdLicense https://scigraph.springernature.com/explorer/license/
37 schema:sdPublisher N27822a09ba954745aa0ef264e8ecd29b
38 schema:url https://link.springer.com/10.1186%2Fs40425-019-0522-3
39 sgo:license sg:explorer/license/
40 sgo:sdDataset articles
41 rdf:type schema:ScholarlyArticle
42 N02b1a9ac208c41c192cfb458d3d0d1af rdf:first N0e772ffc196041e4b47f9523392f558b
43 rdf:rest N616b2c303b3a4571b9b51835832079fa
44 N0e772ffc196041e4b47f9523392f558b schema:affiliation https://www.grid.ac/institutes/grid.270240.3
45 schema:familyName Tykodi
46 schema:givenName Scott S.
47 rdf:type schema:Person
48 N1272b8ce71544748a3435db99c13a019 schema:affiliation https://www.grid.ac/institutes/grid.164971.c
49 schema:familyName Clark
50 schema:givenName Joseph I.
51 rdf:type schema:Person
52 N1a77de563d0f4c9fb763ca3bb38a7688 schema:affiliation https://www.grid.ac/institutes/grid.214458.e
53 schema:familyName Lao
54 schema:givenName Christopher D.
55 rdf:type schema:Person
56 N1d43cc30b6da43f08add5b9e4fb5bb7f schema:name dimensions_id
57 schema:value pub.1112212877
58 rdf:type schema:PropertyValue
59 N20fb31be8a12469ab6853e2fa57cbbba schema:affiliation https://www.grid.ac/institutes/grid.17635.36
60 schema:familyName Holtan
61 schema:givenName Shernan G.
62 rdf:type schema:Person
63 N27822a09ba954745aa0ef264e8ecd29b schema:name Springer Nature - SN SciGraph project
64 rdf:type schema:Organization
65 N30e06d440d004f24a09d5ef5525b3e9e schema:affiliation https://www.grid.ac/institutes/grid.430387.b
66 schema:familyName Silk
67 schema:givenName Ann W.
68 rdf:type schema:Person
69 N345a3364bdb34d49ac751d232c5024c1 schema:affiliation https://www.grid.ac/institutes/grid.468198.a
70 schema:familyName Fishman
71 schema:givenName Mayer N.
72 rdf:type schema:Person
73 N38b9cf2d84c64a72b5018ea44c850127 schema:name pubmed_id
74 schema:value 30777131
75 rdf:type schema:PropertyValue
76 N3b2c4c4f96794349bf4fb5fc0864d0d9 rdf:first Nfcdd261aa02f45fc920b75b5838a37a5
77 rdf:rest Naabd2695c4dc4fecb9da4d25a8917840
78 N4020cfd70f7544b2aea6f89fb474762f schema:affiliation https://www.grid.ac/institutes/grid.266100.3
79 schema:familyName Daniels
80 schema:givenName Gregory A.
81 rdf:type schema:Person
82 N4235053a956f4f90ab29eaa8aafa1a63 schema:affiliation https://www.grid.ac/institutes/grid.262962.b
83 schema:familyName Richart
84 schema:givenName John M.
85 rdf:type schema:Person
86 N4320f0ac0e9a4f4daaf22afc99f4c34b schema:name readcube_id
87 schema:value 146eee18ba798c34ddab163ca5fb25a2f73b2b963ebe466713cabcacbddbd2ae
88 rdf:type schema:PropertyValue
89 N4afe29187e164235945d79a944b2f538 schema:affiliation https://www.grid.ac/institutes/grid.239395.7
90 schema:familyName McDermott
91 schema:givenName David F.
92 rdf:type schema:Person
93 N4f9c057fee594838b46e079f8090ac58 rdf:first N345a3364bdb34d49ac751d232c5024c1
94 rdf:rest Na386e11858564c16b15df5bba6d46598
95 N564422ab292c43a48e55fe59c26e6755 rdf:first N75e94cb66a724b5a8c81b572fddcd368
96 rdf:rest N66929f90216649d687ecaece39edf2d3
97 N5f4a6f5000ca4f57b1ceb18a832a847e rdf:first N1272b8ce71544748a3435db99c13a019
98 rdf:rest N6d39717f093840e5ad14811c092c294d
99 N616b2c303b3a4571b9b51835832079fa rdf:first N30e06d440d004f24a09d5ef5525b3e9e
100 rdf:rest Nc55cdbb6b4864e10a8a67436587b2230
101 N66929f90216649d687ecaece39edf2d3 rdf:first N4020cfd70f7544b2aea6f89fb474762f
102 rdf:rest Ne51e1abf08714e38b047b7640fc66905
103 N6d39717f093840e5ad14811c092c294d rdf:first N4235053a956f4f90ab29eaa8aafa1a63
104 rdf:rest N8895b9a0186c4748adcc395a32780978
105 N749f1ddfd1684347bfeb24b2855838cc schema:affiliation https://www.grid.ac/institutes/grid.415286.c
106 schema:familyName Curti
107 schema:givenName Brendan D.
108 rdf:type schema:Person
109 N75e94cb66a724b5a8c81b572fddcd368 schema:affiliation Nc9adfaefa01b4c25b9d78bcca79dffda
110 schema:familyName Dutcher
111 schema:givenName Janice P.
112 rdf:type schema:Person
113 N774785715d9443e78e55fdda55197122 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
114 schema:familyName Buchbinder
115 schema:givenName Elizabeth I.
116 rdf:type schema:Person
117 N8895b9a0186c4748adcc395a32780978 rdf:first N1a77de563d0f4c9fb763ca3bb38a7688
118 rdf:rest N02b1a9ac208c41c192cfb458d3d0d1af
119 N95e3c952cab6443c87504733d3ee0c70 schema:affiliation https://www.grid.ac/institutes/grid.490187.3
120 schema:familyName Miletello
121 schema:givenName Gerald P.
122 rdf:type schema:Person
123 N9976f5dfd0d84c49b150c8cf2354ae04 schema:name doi
124 schema:value 10.1186/s40425-019-0522-3
125 rdf:type schema:PropertyValue
126 Na386e11858564c16b15df5bba6d46598 rdf:first Nd15b35ece95147f8accc7ed90e159bc3
127 rdf:rest N5f4a6f5000ca4f57b1ceb18a832a847e
128 Naabd2695c4dc4fecb9da4d25a8917840 rdf:first N20fb31be8a12469ab6853e2fa57cbbba
129 rdf:rest Ne456f29b6bda4d2ea78365313999c85f
130 Nc55cdbb6b4864e10a8a67436587b2230 rdf:first N4afe29187e164235945d79a944b2f538
131 rdf:rest rdf:nil
132 Nc9adfaefa01b4c25b9d78bcca79dffda schema:name Cancer Research Foundation of NY, Chappaqua,, NY, USA
133 rdf:type schema:Organization
134 Nd15b35ece95147f8accc7ed90e159bc3 schema:affiliation https://www.grid.ac/institutes/grid.430503.1
135 schema:familyName Gonzalez
136 schema:givenName Rene
137 rdf:type schema:Person
138 Ne311912140b54bdcb339417314276827 schema:issueNumber 1
139 rdf:type schema:PublicationIssue
140 Ne456f29b6bda4d2ea78365313999c85f rdf:first N95e3c952cab6443c87504733d3ee0c70
141 rdf:rest N4f9c057fee594838b46e079f8090ac58
142 Ne51e1abf08714e38b047b7640fc66905 rdf:first N749f1ddfd1684347bfeb24b2855838cc
143 rdf:rest N3b2c4c4f96794349bf4fb5fc0864d0d9
144 Ne844f4e984cc49a083298f38f3e4815d schema:name nlm_unique_id
145 schema:value 101620585
146 rdf:type schema:PropertyValue
147 Nf2d6de3331144867953becb5bc27109d rdf:first N774785715d9443e78e55fdda55197122
148 rdf:rest N564422ab292c43a48e55fe59c26e6755
149 Nf9e45a9dacd844b189c70076f64b4a5e schema:volumeNumber 7
150 rdf:type schema:PublicationVolume
151 Nfcdd261aa02f45fc920b75b5838a37a5 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
152 schema:familyName Patel
153 schema:givenName Sapna P.
154 rdf:type schema:Person
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
159 schema:name Immunology
160 rdf:type schema:DefinedTerm
161 sg:journal.1049249 schema:issn 2051-1426
162 schema:name Journal for ImmunoTherapy of Cancer
163 rdf:type schema:Periodical
164 sg:pub.10.1186/s40425-018-0387-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1105882929
165 https://doi.org/10.1186/s40425-018-0387-x
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1002/(sici)1097-0142(19980815)83:4<797::aid-cncr25>3.0.co;2-m schema:sameAs https://app.dimensions.ai/details/publication/pub.1015678740
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/0092-8674(93)90152-g schema:sameAs https://app.dimensions.ai/details/publication/pub.1016163477
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1016/s0140-6736(14)60958-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012632588
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1016/s1470-2045(16)30126-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002679693
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1056/nejmoa1003466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052212829
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1056/nejmoa1414428 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007696832
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1056/nejmoa1504030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024843336
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1056/nejmoa1510665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019970557
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1158/1078-0432.ccr-11-1823 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010268280
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1172/jci67008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046164943
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1200/jco.1995.13.3.688 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082550218
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1200/jco.2013.53.0105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047895673
190 rdf:type schema:CreativeWork
191 https://www.grid.ac/institutes/grid.164971.c schema:alternateName Loyola University Chicago
192 schema:name Loyola University Stritch School of Medicine, Maywood, IL, USA
193 rdf:type schema:Organization
194 https://www.grid.ac/institutes/grid.17635.36 schema:alternateName University of Minnesota
195 schema:name University of Minnesota, Minneapolis, MN, USA
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.214458.e schema:alternateName University of Michigan–Ann Arbor
198 schema:name University of Michigan, Ann Arbor, MI, USA
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.239395.7 schema:alternateName Beth Israel Deaconess Medical Center
201 schema:name Beth Israel Deaconess Medical Center, Boston, MA, USA
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
204 schema:name The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.262962.b schema:alternateName Saint Louis University
207 schema:name Saint Louis University, 63110, Saint Louis, MO, USA
208 rdf:type schema:Organization
209 https://www.grid.ac/institutes/grid.266100.3 schema:alternateName University of California, San Diego
210 schema:name Moores UCSD Cancer Center, La Jolla, San Diego, CA, USA
211 rdf:type schema:Organization
212 https://www.grid.ac/institutes/grid.270240.3 schema:alternateName Fred Hutchinson Cancer Research Center
213 schema:name University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA
214 rdf:type schema:Organization
215 https://www.grid.ac/institutes/grid.415286.c schema:alternateName Providence Health & Services
216 schema:name Providence Health & Services, Portland, OR, USA
217 rdf:type schema:Organization
218 https://www.grid.ac/institutes/grid.430387.b schema:alternateName Rutgers University
219 schema:name Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
220 rdf:type schema:Organization
221 https://www.grid.ac/institutes/grid.430503.1 schema:alternateName University of Colorado Anschutz Medical Campus
222 schema:name University of Colorado, Aurora, CO, USA
223 rdf:type schema:Organization
224 https://www.grid.ac/institutes/grid.468198.a schema:alternateName Moffitt Cancer Center
225 schema:name Moffitt Cancer Center, Tampa, FL, USA
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.490187.3 schema:alternateName Hematology\Oncology Clinic
228 schema:name Hematology/Oncology Clinic, Baton Rouge, LA, USA
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
231 schema:name Dana Farber Cancer Institute, Boston, MA, USA
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...